A critical aspect of validating the therapeutic activity of a new agent is to be able to directly correlate the expression of the test agent with the biological effect. In the matter of RNA interference therapeutics, quantification of intracellular expression and/or localization of the RNAi molecules has been problematic due to the small size of the RNAi.
The specific aims i n Core C will be:
Aim 1 : To oversee the production methods and acquisition of cGMP reagents necessary for the phase 1 trial: ITI has established an agreement with Xcyte Therapies Inc. for the use of their proprietary cGMP-quality anti-CD3/anti-CD28 coated beads. These will be used for T cell expansion. All technology and procedures necessary for the expansion of these cells will be the responsibility of ITI and Core C will interact closely with Core C for the actual transduction and expansion of these cells.
Aim 2 : To perform quantitative measurements of RNAi necessary for the evaluation of lentivirus vectors developed in projects 1 and 2 and safety tested in Project 4: ITI has developed a proprietary technology called ProxiQuantTM that is able to measure small RNA molecules and which will be required for all pre-clinical and clinical assessment of vector induced RNAi expression efficiency. This is the only such technology forstandardization of transgene expression in this field.
Aim 3 : To execute the procedures for T cell transduction and expansion necessary for phase 1 clinical trials: The facilities of the CBG at BRICOH has considerable expertise in expansion of transduced T cells under cGMP conditions, and will be used for all production of the clinical grade products. The CBG has a BL-3 level areawithin the cGMP laboratories that will be used for these expansions. The clinical IND will cross reference the methods already approved by the FDA for ongoing T cell immunotherapy projects.
Aim 4 : To coordinate the completion of the IND application, to maintain and monitor operations according to cGMP regulations, and to interact with the FDA on behalf of the P.I. for regulatory matters: ITI has experience in FDA applications and study implementation and will be responsible for seeing that all target deadlines and regulatory requirements are properly observed. Thus, the core will serve as a valuable resource as a liaison with the FDA for issues related to the phase 1 trial.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
1P01AI061839-01
Application #
6850635
Study Section
Special Emphasis Panel (ZAI1-TS-A (M4))
Project Start
2004-08-01
Project End
2008-07-31
Budget Start
2004-08-01
Budget End
2005-07-31
Support Year
1
Fiscal Year
2004
Total Cost
$202,442
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
DiGiusto, David L; Stan, Rodica; Krishnan, Amrita et al. (2013) Development of hematopoietic stem cell based gene therapy for HIV-1 infection: considerations for proof of concept studies and translation to standard medical practice. Viruses 5:2898-919
Zheng, Weiyan; Wang, Yingjia; Chang, Tammy et al. (2013) Significant differences in genotoxicity induced by retrovirus integration in human T cells and induced pluripotent stem cells. Gene 519:142-9
Trobridge, Grant D; Horn, Peter A; Beard, Brian C et al. (2012) Large animal models for foamy virus vector gene therapy. Viruses 4:3572-88
Kiem, Hans-Peter; Ironside, Christina; Beard, Brian C et al. (2010) A retroviral vector common integration site between leupaxin and zinc finger protein 91 (ZFP91) observed in baboon hematopoietic repopulating cells. Exp Hematol 38:819-22, 822.e1-3
Trobridge, Grant D; Wu, Robert A; Hansen, Michael et al. (2010) Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells. Mol Ther 18:725-33
DiGiusto, David L; Krishnan, Amrita; Li, Lijing et al. (2010) RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2:36ra43
Beard, Brian C; Trobridge, Grant D; Ironside, Christina et al. (2010) Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J Clin Invest 120:2345-54
Trobridge, G D; Kiem, H-P (2010) Large animal models of hematopoietic stem cell gene therapy. Gene Ther 17:939-48
Kiem, H-P; Wu, R A; Sun, G et al. (2010) Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo. Gene Ther 17:37-49
Bonig, Halvard; Watts, Korashon L; Chang, Kai-Hsin et al. (2009) Concurrent blockade of alpha4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization. Stem Cells 27:836-7

Showing the most recent 10 out of 20 publications